Stocks Health care LIPO
Health careLipella Pharmaceuticals Inc. (LIPO)
It posted a net loss of $5.3M. At September 30, 2025 it held $1.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 14, 2025.
What Lipella Pharmaceuticals Inc. does
Lipella Pharmaceuticals Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations).
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2024 | $536.4K | -$5M | -$4.79 | n/a |
| 2023 | $449.6K | -$4.6M | -$6.16 | -$3.2M |
| 2022 | $184.2K | -$2.6M | -$5.12 | n/a |
| 2022 | $259.3K | -$1.9M | -$4.40 | n/a |
Latest SEC filings
What Lipella Pharmaceuticals Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- July 15, 2026
- March 31, 2026
- February 4, 2026
- November 14, 2025Quarterly report 10-Q · period to September 30, 2025
- October 21, 2025
- October 9, 2025
- October 6, 2025Delisting notice 25-NSE
- September 18, 2025
- August 14, 2025Quarterly report 10-Q · period to June 30, 2025
- June 25, 2025
Questions about LIPO
What does Lipella Pharmaceuticals Inc. do?
Lipella Pharmaceuticals Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations).
Is Lipella Pharmaceuticals Inc. profitable?
No. Over the twelve months to September 30, 2025 it reported a net loss of $5.3M.
When did Lipella Pharmaceuticals Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 14, 2025. It covers the period to September 30, 2025. Its newest filing of any kind is the bankruptcy or receivership from July 15, 2026.
Similar companies
Follow LIPO
Get an email when Lipella Pharmaceuticals Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow LIPO: get an email when it filesWhere the numbers come from
Financial figures are the values Lipella Pharmaceuticals Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.